Zobrazeno 1 - 10
of 149
pro vyhledávání: '"John C. Byrd"'
Autor:
James S. Blachly, Uma Borate, Eunice S. Wang, Bhavana Bhatnagar, Ross L. Levine, Ann-Kathrin Eisfeld, Amy Burd, John C. Byrd, Richard Stone, Brian J. Druker, Alice S. Mims, Krzysztof Mrόzek, Eytan M. Stein, Bayard L. Powell, Jonathan E. Kolitz, Clara D. Bloomfield, Shelley Orwick, Jessica Kohlschmidt, Dimitrios Papaioannou, Deedra Nicolet
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-15 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Older patients (≥ 60 years) with acute myeloid leukemia (AML) often have multiple, sequentially acquired, somatic mutations that drive leukemogenesis and are associated with poor outcome. Beat AML is a Leukemia and Lymphoma Society-spons
Autor:
James S. Blachly, Anna Reister Schultz, Maximilian Schmutz, Christopher C. Oakes, Brian J. Druker, Bethany L. Mundy-Bosse, Min Wang, Sebastian Vosberg, Ramiro Garzon, Lars Bullinger, Philipp A. Greif, Ann-Kathrin Eisfeld, Rainer Claus, John C. Byrd, Clara D. Bloomfield, Yue Zhong Wu, Kevin R. Coombes, Brian Giacopelli, Ada C Cleary, Jeffrey W. Tyner
Publikováno v:
Genome Res
Genome Res. 31, 747-761 (2021)
Genome Res. 31, 747-761 (2021)
Acute myeloid leukemia (AML) is a molecularly complex disease characterized by heterogeneous tumor genetic profiles and involving numerous pathogenic mechanisms and pathways. Integration of molecular data types across multiple patient cohorts may adv
Autor:
Bhavana Bhatnagar, Arati V. Rao, James S. Blachly, Tara L. Lin, Alison Walker, Howland E. Crosswell, William Blum, Jinfeng Liu, Veerendra Munugalavadla, Lauren Long, Danjie Zhang, Mark D. Minden, Yang Pan, Hubert Serve, John C. Byrd, Alice S. Mims, Thomas Oellerich, Shelley Orwick
Publikováno v:
Clinical Cancer Research. 26:5852-5859
Purpose: Spleen tyrosine kinase (SYK) signaling is a proposed target in acute myeloid leukemia (AML). Sensitivity to SYK inhibition has been linked to HOXA9 and MEIS1 overexpression in preclinical studies. This trial evaluated the safety and efficacy
Autor:
Jordan Chervin, Ross L. Levine, Tara L. Lin, Ying Huang, William Blum, Sonja Marcus, Tibor Kovacsovics, Ashley O. Yocum, Franchesca Druggan, Gary J. Schiller, Brian J. Druker, Mona Stefanos, Uma Borate, Matthew C. Foster, Mark R. Litzow, John C. Byrd, Nyla A. Heerema, Robert H. Collins, Abigail B. Shoben, Wendy Stock, Leonard Rosenberg, Amy Burd, Michael Boyiadzis, James M. Foran, Rebecca L. Olin, Jo-Anne Vergilio, Prapti A. Patel, Maria R. Baer, Timothy L. Chen, Eytan M. Stein, Alice S. Mims
Publikováno v:
Blood. 136:27-30
Background: ENA is an oral, selective inhibitor of IDH2 approved for the treatment (Tx) of patients (pts) with relapsed/refractory IDH2 mutated (IDH2m) AML. Here we report the results of a Phase 2 expansion and Phase 1b of the Beat AML Master Trial P
Autor:
Anasuya Sarkar, Rakesh A Murugesan, Giovanna Merchand-Reyes, John C. Byrd, Sumithira Vasu, Jonathan P. Butchar, Susheela Tridandapani, Gino M Dettorre, Bethany L. Mundy-Bosse, Nathaniel J Buteyn, Ramasamy Santhanam
Publikováno v:
J Immunol
TLRs, a family of membrane-bound pattern recognition receptors found on innate immune cells, have been well studied in the context of cancer therapy. Activation of these receptors has been shown to induce inflammatory anticancer events, including dif
Autor:
Arati V. Rao, Thomas Oellerich, S. Haihua Chu, Alison Walker, Anjali Cremer, Federica Piccioni, Amy Goodale, Gabriela Alexe, James S. Blachly, Björn Häupl, Linda Ross, Elizabeth S. Frank, Amanda L. Robichaud, John C. Byrd, Scott A. Armstrong, Yana Pikman, Jana M. Ellegast, Kimberly Stegmaier, Sebastian Mohr
Publikováno v:
Cancer Discov
Spleen tyrosine kinase (SYK) is a nonmutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising results in combination with chemotherapy, likely reflecting induced mechanisms of res
Publikováno v:
J Natl Compr Canc Netw
Acute undifferentiated leukemia (AUL) is a subtype of acute leukemias of ambiguous lineage. There is no standard treatment approach for AUL, although acute lymphoblastic leukemia–like regimens for induction therapy have been used. Additional data s
Autor:
Jessica Kohlschmidt, Richard Stone, Dimitrios Papaioannou, Clara D. Bloomfield, Adrienne M. Dorrance, Marius Bill, Bayard L. Powell, Andrew J. Carroll, Deedra Nicolet, Jonathan E. Kolitz, Ramiro Garzon, John C. Byrd, Ann-Kathrin Eisfeld, Zachary Brannan, Xiaoqing Rong-Mullins, Krzysztof Mrózek, Kellie J. Archer, Christopher J. Walker
Publikováno v:
Haematologica
Leukemia stem cells (LSC) are more resistant to standard chemotherapy and their persistence during remission can cause relapse, which is still one of the major clinical challenges in the treatment of acute myeloid leukemia (AML). A better understandi
Autor:
William Blum, John C. Byrd, Sumithira Vasu, Gregory K. Behbehani, Rebecca B. Klisovic, Karilyn Larkin, Ramiro Garzon, Amy S. Ruppert, Alice S. Mims, Qiuhong Zhao, James S. Blachly, Shelley Orwick, Bhavana Bhatnagar, Christopher C. Oakes, Parvathi Ranganathan, Alison Walker
Publikováno v:
Leuk Lymphoma
Current treatment options for older and relapsed or refractory (R/R) acute myeloid leukemia (AML) patients are limited and represent an unmet need. Based on preclinical studies showing strong anti-leukemic effects in vivo, this phase I dose-escalatio
Autor:
James S. Blachly, Andrew J. Carroll, John C. Byrd, Christopher C. Oakes, Sydney Fobare, Shelley Orwick, Richard Stone, Krzysztof Mrózek, Alice S. Mims, Eunice S. Wang, Hatice Gulcin Ozer, Bayard L. Powell, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Ramiro Garzon, Jessica Kohlschmidt, Deedra Nicolet, Erin Hertlein
Publikováno v:
Blood advances. 6(5)
Prognostic factors associated with chemotherapy outcomes in patients with acute myeloid leukemia (AML) are extensively reported, and one gene whose mutation is recognized as conferring resistance to several newer targeted therapies is protein tyrosin